Health Care • Biotechnology: Pharmaceutical Preparations
$10.43 ▼ -0.31
(-2.89%)
MKT CAP: $735.7M • VOL: 746.5K
52W L $5 52W H $11
ROARABLE / RQD
E • 34/100
PIOTROSKI
2 / 9
SGMT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $2.0M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$56.9M | -$54.5M | -$30.7M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$51.0M | -$45.6M | -$27.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$45.6M | -$42.4M | -$23.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$45.6M | -$42.4M | -$23.8M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $35.0M | $75.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $111.4M | $155.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SGMT.